On Tuesday, Beam Therapeutics Inc (NASDAQ: BEAM) opened lower -4.45% from the last session, before settling in for the closing price of $24.50. Price fluctuations for BEAM have ranged from $16.95 to $49.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 43297.50%. Company’s average yearly earnings per share was noted -173.40% at the time writing. With a float of $71.60 million, this company’s outstanding shares have now reached $81.63 million.
Let’s determine the extent of company efficiency that accounts for 436 employees.
Beam Therapeutics Inc (BEAM) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Beam Therapeutics Inc is 13.13%, while institutional ownership is 81.31%. The most recent insider transaction that took place on Sep 30 ’24, was worth 1,476,024. Before that another transaction happened on Jul 02 ’24, when Company’s Chief Medical Officer sold 748 for $22.95, making the entire transaction worth $17,167. This insider now owns 68,805 shares in total.
Beam Therapeutics Inc (BEAM) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -173.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.70% during the next five years compared to 5.58% growth over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Check out the current performance indicators for Beam Therapeutics Inc (BEAM). In the past quarter, the stock posted a quick ratio of 5.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.80, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -4.67 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Looking closely at Beam Therapeutics Inc (NASDAQ: BEAM), its last 5-days average volume was 0.75 million, which is a drop from its year-to-date volume of 1.26 million. As of the previous 9 days, the stock’s Stochastic %D was 16.05%. Additionally, its Average True Range was 1.28.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 17.27%, which indicates a significant increase from 7.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.92% in the past 14 days, which was lower than the 61.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.04, while its 200-day Moving Average is $27.20. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $24.17. Second resistance stands at $24.92. The third major resistance level sits at $25.45. If the price goes on to break the first support level at $22.89, it is likely to go to the next support level at $22.36. Should the price break the second support level, the third support level stands at $21.61.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
There are currently 82,311K shares outstanding in the company with a market cap of 1.93 billion. Presently, the company’s annual sales total 377,710 K according to its annual income of -132,530 K. Last quarter, the company’s sales amounted to 11,770 K and its income totaled -91,050 K.
